To date, there have been approximately 226 patients diagnosed with Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy (NSF/NFD), possibly associated with intravenous Gadolinium MR Contrast administration. In the past 20 years, millions of Gadolinium containing contrast injections have been administered. The FDA believes that there is some risk of this complication (NSF/NFD) related to these contrast agents. All such patients have had moderate to end stage renal dysfunction.
Based on this alert, and after consultation with nephrology, a new screening policy will be instituted at John Muir Magnetic Imaging Center, Contra Costa Imaging Center and John Muir Medical Center, Brentwood Campus for all patients referred for contrast enhanced MRI.
All patients referred for examinations with Gadolinium based contrast media will be screened for the following indications:
- Over the age of 60
- Under the age of 60 with:
- Known or suspected renal insufficiency
- Diabetes mellitus
- Scheduled for MRA arteriography including but not limited to:
- MRA aortofemoral runoff
- MRA for asymmetric renal arterial stenosis
All Outpatients meeting any of the above criteria will be required to have a Creatinine/eGFR Lab work within 30 days prior to a contrast enhanced MRI. Inpatients will require the same lab work within 2 days. It is the ordering physician's responsibility to order the necessary lab work prior to the MRI exam.
Please contact us if you have any questions about our new screening policy.
Contra Costa Imaging Center
Phone (925) 687-5600
John Muir Magnetic Imaging Center
Phone (925) 295-1545
John Muir Medical Center, Brentwood Campus Medical Imaging
Phone (925) 308-8123